In adult models of stroke, the use of ephrin-A5 antagonists [49], GABAα5 inverse agonists [50], histone deacetylase 5 inhibitors [51], or C-C chemokine receptor 5 (CCR5) knockdown [52] at delayed time points augmented motor recovery. The gene discussed is CCR5; the disease is stroke disorder.